Please login to the form below
Vivet Therapeutics
This page shows the latest Vivet Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Pfizer goes big on gene therapy with $500m facility spend
That was followed swiftly by a partnership with Spark Therapeutics that brought in a clinical-stage haemophilia B therapy now in phase 3 testing, and another deal with Sangamo for a ... It also took a 15% stake in Vivet Therapeutics and its lead
Latest news
-
Pfizer buys dwarfism drug company Therachon for $810m
a 15% stake in Vivet Therapeutics earlier this year, and in-house mini-dystrophin gene therapy candidate PF-06939926 for Duchenne muscular dystrophy.
-
Catalent preps for complex therapy boom with $1.2bn Paragon buy
Last month, Pfizer paid around $640m for a 15% stake in Vivet Therapeutics, while Biogen snapped up Nightstar Therapeutics for $800m and Roche acquired Spark Therapeutics in February for $4.3bn. ... And in 2018, Novartis’ bought AveXis for $8.7bn to
-
Pfizer hedges bets on gene therapy deal
Company not splashing out like Roche's Spark purchase. Pfizer has stopped short of joining 2019's gene therapy buying spree, instead acquiring a 15% of Vivet Therapeutics, and securing an ... Vivet Therapeutics’ lead candidate is VTX-801, a gene
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
